NuCana (NCNA) Other Non Operating Income (2017 - 2025)
NuCana (NCNA) reported Other Non Operating Income of $57197.1 for Q4 2025, down 89.8% on a YoY basis from $560890.3 in Q4 2024, and down 57.61% sequentially from $134936.2 in Q3 2025.
NuCana (NCNA) Other Non Operating Income (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Other Non Operating Income data on file, last reported at $57197.1 in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income fell 89.8% year-over-year to $57197.1; the trailing twelve-month figure through Dec 2025 stood at -$151654.4 (down 152.21% YoY), and the FY2025 full-year result was $255791.0, up 154.23% from the prior year.
- Other Non Operating Income slipped to $57197.1 in Q4 2025, from $134936.2 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $3.9 million in Q2 2022 to a low of -$2.6 million in Q4 2022.
- A 5-year average of -$56852.5 and a median of -$83857.4 in 2024 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 2643.39% in 2022, while the deepest fall reached 779.17% in 2022.
- Tracing NCNA's Other Non Operating Income over 5 years: stood at -$297910.3 in 2021, then sank by 779.17% to -$2.6 million in 2022, then soared by 78.25% to -$569688.7 in 2023, then soared by 198.46% to $560890.3 in 2024, then slumped by 89.8% to $57197.1 in 2025.
- Business Quant data shows NCNA's Other Non Operating Income at $57197.1 in Q4 2025, $134936.2 in Q3 2025, and -$269477.2 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 57,197.15 |
| Sep 30, 2025 | 134,936.21 |
| Jun 30, 2025 | -269,477.23 |
| Mar 31, 2025 | -74,310.53 |
| Dec 31, 2024 | 560,890.30 |
| Sep 30, 2024 | -297,539.74 |
| Jun 30, 2024 | -93,404.34 |
| Mar 31, 2024 | 120,509.23 |
| Dec 31, 2023 | -569,688.72 |
| Sep 30, 2023 | 711,876.85 |
| Jun 30, 2023 | -705,768.82 |
| Mar 31, 2023 | 882,459.91 |
| Dec 31, 2022 | -2.62 Mn |
| Sep 30, 2022 | 61,284.51 |
| Jun 30, 2022 | 3.87 Mn |
| Mar 31, 2022 | -1.54 Mn |
| Dec 31, 2021 | -297,910.34 |
| Sep 30, 2021 | 13,785.83 |
| Jun 30, 2021 | -152,352.38 |
| Mar 31, 2021 | -933,529.36 |